Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

Testosterone recovery was associated with improved OS in patients with high-risk prostate cancer treated with ADT and radiotherapy.

The median radiographic progression-free survival was 4.6 years in patients who received stereotactic body radiotherapy and 2.3 years in patients who did not. Adding metastasis-directed ...

Health Reform Will Provide Cancer Screening Services to Millions of Newly-Insured Women - but National Low-Income Screening Program Still 'Essential' ...

Patients with higher PORTOS scores had superior clinical progression-free survival if they received salvage radiotherapy at a higher dose. The gene expression signature PORTOS can determine which ...

Patients who received talazoparib had a roughly 9-month improvement in overall survival and a roughly 14-month improvement in radiographic progression-free survival. Adding talazoparib to first ...